Strona 1 od 413 wyniki
Worldwide, lung cancer is the most commonly diagnosed cancer. In NSCLC the most prevalent actionable driver mutations result in the activation of epidermal growth factor receptor (EGFR). Osimertinib and Lazertinib are EGFR tyrosine kinase inhibitors (TKIs). Amivantamab is a novel bispecific antibody
The prognosis of stage Ⅱa-Ⅲb Non-small cell lung cancer (NSCLC) was worse, with 5-year survival rate between 26%-60%. The recommended adjuvant therapy for stage Ⅱa-Ⅲb NSCLC were adjuvant or neoadjuvant chemotherapy. As for advanced NSCLC with EGFR activating mutation, EGFR-TKI combination with
This is a phase II pilot study to evaluate the efficacy and safety of osimertinib with bevacizumab for LM from EGFRm NSCLC patients. ALL patients were treated with Osimertinib 80mg oral daily and bevacizumab 7.5mg/kg intravenous every 3 weeks. Study therapy continued until disease progression,
This is a phase II, open-label, multicenter, single-arm, prospective clinical study designed to investigate the efficacy and safety of Tislelizumab (anti-PD1 antibody) combined with carboplatin plus Nab-paclitaxel in Non-squamous NSCLC patients with EGFR sensitizing mutation who failed EGFR TKI
Lung cancer is the most leading malignant tumor, among which small cell lung cancer accounts for about 15%. Approximately 65% of new patients were diagnosed with ES-SCLC at the first visit with less than 6 months of median PFS (mPFS) and 8-13 months of median OS (mOS). Platinum combined with
The brain is a common site of metastases among patients with non-small-cell lung cancer (NSCLC).The incidence of CNS metastases in patients with EGFR mutation-positive NSCLC is 24% at first diagnosis almost doubles over the course of the disease. Several data has shown treatment with first
Background: Lung cancer is a leading cause of cancer-related morbidity and mortality. There are 2 main categories of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for approximately 85% of lung cancer diagnoses, almost 70% of NSCLC cases are
Classic Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) (Levine et al., 2007).
According to WHO 2016 classification which also included chronic
The frequency of EGFR mutations in patients with stage III inoperable adenocarcinoma or non-squamous cell carcinoma is 17-31%, which is relatively low. Compared to patients with EGFR wild type, the efficacy of radiotherapy or chemo-radiotherapy may be different in EGFR mutant patients. Some small
Section 1:title and overview Title: Relationship between histopathological features, mutation status, 18F-FDG PET/CT radiomic imaging parameters as well as clinical outcome in patients with treatment-naïve non-small cell lung cancer(NSCLC).
Overview: Nowadays, the most increasingly rapid incidence
Lung cancer is not only amongst the top 3 most common cancer type in both men and women, but also the leading cause of cancer mortality in Singapore and the United States. Platinum-based chemotherapy is currently the mainstay in drug treatment for lung cancer patients although it only relieves